Vigil Neuroscience Shares Surge After Sanofi's Planned Acquisition

Dow Jones

May 22, 2025

By Denny Jacob

Vigil Neuroscience shares more than tripled in premarket trading a day after Sanofi agreed to acquire Vigil for about $470 million.

Vigil shares were trading around $8. The stock was up 36% on the year as of Wednesday's close.

Paris-based Sanofi said Wednesday evening that it would purchase all of the clinical-stage biotechnology company's outstanding shares for an upfront payment of $8 a share. Vigil shareholders will also receive the right to an additional $2 a share in cash, payable following the first commercial sale of the in-development Alzheimer's treatment VG-3927, if achieved within a set period.

Including the possible later payout, the deal's total equity value could reach about $600 million, said Watertown, Mass.-based Vigil. The sale is expected to close in the third quarter.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

May 22, 2025 07:47 ET (11:47 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2537945889"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537945889\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537945889?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-22 19:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537945889","market":"fut","top_or_hot":-1,"title":"Vigil Neuroscience Shares Surge After Sanofi's Planned Acquisition","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Vigil Neuroscience shares more than tripled in premarket trading a day after <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> agreed to acquire Vigil for about $470 million. \n</p>\n<p>\n  Vigil shares were trading around $8. The stock was up 36% on the year as of Wednesday's close. \n</p>\n<p>\n  Paris-based Sanofi said Wednesday evening that it would purchase all of the clinical-stage biotechnology company's outstanding shares for an upfront payment of $8 a share. Vigil shareholders will also receive the right to an additional $2 a share in cash, payable following the first commercial sale of the in-development Alzheimer's treatment VG-3927, if achieved within a set period. \n</p>\n<p>\n  Including the possible later payout, the deal's total equity value could reach about $600 million, said Watertown, Mass.-based Vigil. The sale is expected to close in the third quarter. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 22, 2025 07:47 ET (11:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vigil Neuroscience Shares Surge After Sanofi's Planned Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVigil Neuroscience Shares Surge After Sanofi's Planned Acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-22 19:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Vigil Neuroscience shares more than tripled in premarket trading a day after <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> agreed to acquire Vigil for about $470 million. \n</p>\n<p>\n  Vigil shares were trading around $8. The stock was up 36% on the year as of Wednesday's close. \n</p>\n<p>\n  Paris-based Sanofi said Wednesday evening that it would purchase all of the clinical-stage biotechnology company's outstanding shares for an upfront payment of $8 a share. Vigil shareholders will also receive the right to an additional $2 a share in cash, payable following the first commercial sale of the in-development Alzheimer's treatment VG-3927, if achieved within a set period. \n</p>\n<p>\n  Including the possible later payout, the deal's total equity value could reach about $600 million, said Watertown, Mass.-based Vigil. The sale is expected to close in the third quarter. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 22, 2025 07:47 ET (11:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFXG1179.USD","symbol_name":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2537945889","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537945889","pubTimestamp":1747914420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Vigil Neuroscience shares more than tripled in premarket trading a day after Sanofi agreed to acquire Vigil for about $470 million.Vigil shares were trading around $8. The stock was up 36% on the year as of Wednesday's close.Paris-based Sanofi said Wednesday evening that it would purchase all of the clinical-stage biotechnology company's outstanding shares for an upfront payment of $8 a share. Vigil shareholders will also receive the right to an additional $2 a share in cash, payable following the first commercial sale of the in-development Alzheimer's treatment VG-3927, if achieved within a set period.Including the possible later payout, the deal's total equity value could reach about $600 million, said Watertown, Mass.-based Vigil. The sale is expected to close in the third quarter.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","BK4007":"制药","VIGL":"Vigil Neuroscience, Inc.","SNY":"赛诺菲安万特","SNYNF":"Sanofi","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"赛诺菲计划收购后Vigil Neuroscience股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1,"SNY":0.9,"VIGL":0.9},"content_text":"By Denny Jacob \n\n\n \n\n\n  Vigil Neuroscience shares more than tripled in premarket trading a day after Sanofi agreed to acquire Vigil for about $470 million. \n\n\n  Vigil shares were trading around $8. The stock was up 36% on the year as of Wednesday's close. \n\n\n  Paris-based Sanofi said Wednesday evening that it would purchase all of the clinical-stage biotechnology company's outstanding shares for an upfront payment of $8 a share. Vigil shareholders will also receive the right to an additional $2 a share in cash, payable following the first commercial sale of the in-development Alzheimer's treatment VG-3927, if achieved within a set period. \n\n\n  Including the possible later payout, the deal's total equity value could reach about $600 million, said Watertown, Mass.-based Vigil. The sale is expected to close in the third quarter. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 22, 2025 07:47 ET (11:47 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}